Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML. Issue 6 (12th May 2021) - Ladha, Abdullah; Hui, Gavin; Cheung, Edna; Berube, Caroline; Coutre, Steven E.; Gotlib, Jason; Liedtke, Michaela; Zhang, Tian Y.; Muffly, Lori; Mannis, Gabriel N.